Hematological Neoplasms Clinical Trial
Official title:
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs based on the opportunistic sampling strategy in children with confirmed or suspected hematological neoplasms. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00410696 -
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
|
Phase 2 | |
| Completed |
NCT00440479 -
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
|
Phase 4 | |
| Completed |
NCT02223052 -
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT00440765 -
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
|
Phase 4 | |
| Completed |
NCT02544230 -
Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia
|
N/A | |
| Completed |
NCT00582894 -
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
|
N/A | |
| Completed |
NCT02634294 -
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
|
Phase 2/Phase 3 |